Transforming growth factor-β signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion

Molecular Cancer Research

Volumn 6, Issue 10, 2008, Pages 1521-1533

  Cheng, Nikki ^a,c   Chytil, Anna ^a,c   Shyr, Yu ^a,c   Joly, Alison ^d   Moses, Harold L ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

^d EXELIXIS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; PROTEIN RON; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FIBROBLAST; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CULTURE MEDIA, CONDITIONED; FEMALE; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; MAMMARY NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 54249093237     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-2203     Document Type: Article

References (48)

1. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005;15:97-101.
2. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
3. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002;32:355-7.
4. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000;60:1254-60.
5. Camps J, Chang S, Hsu T, et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A 1990;87:75-79.
6. Tuxhorn J, Ayala G, Smith M, Smith V, Dang T, Rowley D. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002a;8:2912-23.
7. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004;117:1495-502.
8. Sakakura T, Sakagami Y, Nishizuka Y. Accelerated mammary cancer development by fetal salivary mesenchyma isografted to adult mouse mammary epithelium. J Natl Cancer Inst 1981;66:953-9.
9. Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001;61:1320-6.
10. Daniel CW, Robinson S, Silberstein GB. The transforming growth factors β in development and functional differentiation of the mouse mammary gland. In: Bioactive components of human milk. New York: Plenum Publishers; 2001. p. 61-9.
11. Pollard J. Tumour-stromal interactions. Transforming growth factor-β isoforms and hepatocyte growth factor/scatter factor in mammary gland ductal morphogenesis. Breast Cancer Res 2001;3:230-7.
12. Abraham S, Sawaya BE, Safak M, Batuman O, Khalili K, Amini S. Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial cells. Virology 2003;309:196-202.
13. Akhurst RJ, Derynck R. TGF-B signaling in cancer- a double edged sword. Trends Cell Biol 2001;11:S44-50.
14. Ihn H. Pathogenesis of fibrosis: role of TGF-β and CTGF. Curr Op Rheum 2002;14:681-5.
15. Chytil A, Magnuson MA, Wright CVE, Moses HL. Conditional inactivation of the TGF-B type II receptor using Cre-Lox. Genesis 2002;32:73-5.
16. Bhowmick N, Chytiil A, Plieth D, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:847-51.
17. Cheng N, Bhowmick NA, Chytil A, et al. Loss of TGF-β type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-α-, MSP- and HGF-mediated signaling networks. Oncogene 2005;24:5053-68.
18. Rosario M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003;13:328-35.
19. Soriano JV, Pepper MS, Orci L, Montesano R. Roles of hepatocyte growth factor/scatter factor and transforming growth factor-β1 in mammary gland ductal morphogenesis. J Mammary Gland Biol Neoplasia 1998;3:133-50.
20. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225:1-26.
21. Date K, Matsumoto K, Kuba K, Shimura H, Tanaka M, Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998;17:3045-54.
22. Wang M, Wang D, Chen Y. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the Ron receptor tyrosine kinase. Carcinogenesis 2003;23:1291-300.
23. Mazzone M, Basilico C, Cavassa S, et al. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 2004;114:1418-32.
24. Maggiora P, Lorenzato A, Fracchioli S, et al. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res 2003;288:382-9.
25. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Crosstalk between the proto-oncogenes Met and Ron. Oncogene 2000;19:3041-9.
26. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-{β} receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res 2007;67:4869-77.
27. Joseph H, Gorska AE, Sohn P, Moses HL, Serra R. Overexpression of a kinase-deficient transforming growth factor-B type II receptor in mouse mammary stroma results in increased epithelial branching. Mol Biol Cell 1999;10:1221-34.
28. Catalano RD, Johnson MH, Campbell EA, Charnock-Jones DS, Smith SK, Sharkey AM. Inhibition of Stat3 activation in the endometrium prevents implantation: a nonsteroidal approach to contraception. Proc Natl Acad Sci U S A 2005;102:8585-90.
29. Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003;9:316-26.
30. Jó M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Crosstalk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000;275:8806-11.
31. Bonine-Summers AR, Aakre ME, Brown KA, et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 2007;6:561-70.
32. Shirakawa K, Wakasugi H, Heike Y, et al. Vasculogenic mimicry and pseudocomedo formation in breast cancer. Int J Cancer 2002;99:821-8.
33. Camp ER, Liu W, Fan F, Yang A, Somcio R, Ellis LM. RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 2005;12:273- 81.
34. Tate A, Isotani S, Bradley MJ, et al. Met-independent hepatocyte growth factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer 2006;6:197.
35. Gaudino G, Follenzi A, Naldini L, et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 1994;13:3524-32.
36. Wang MH, Ronsin C, Gesnel MC, et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 1994;266:117-9.
37. Wielenga VJ, van der Voort R, Taher TE, et al. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am J Pathol 2000;157:1563-73.
38. Arany I, Megyesi JK, Nelkin BD, Safirstein RL. STAT3 attenuates EGFR-mediated ERK activation and cell survival during oxidant stress in mouse proximal tubular cells. Kidney Int 2006;70:669-74.
39. Nakagami H, Morishita R, Yamamoto K, et al. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension 2001;37:581-6.
40. Quadros MR, Peruzzi F, Kari C, Rodeck U. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res 2004;64:3934-9.
41. Yeoh GC, Ernst M, Rose-John S, et al. Opposing roles of gp130-mediated STAT-3 and ERK-1/2 signaling in liver progenitor cell migration and proliferation. Hepatology 2007;45:486-94.
42. Ray RM, Vaidya RJ, Johnson LR. MEK/ERK regulates adherens junctions and migration through Rac1. Cell Motil Cytoskeleton 2006;64:143-56.
43. Debidda M, Wang L, Zang H, Poli V, Zheng Y. A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J Biol Chem 2005;280:17275-85.
44. Lakka SS, Jasti SL, Gondi C, et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 2002;21:5601-8.
45. Xie TX, Wei D, Liu M, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004;23:3550-60.
46. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
47. Bannen LC, DS, Chen J, Dalrymple L. c-Met modulators and methods of use. US Patent WO2005030140.
48. Santos OF, Moura LA, Rosen EM, Nigam SK. Modulation of HGF-induced tubulogenesis and branching by multiple phosphorylation mechanisms. Dev Biol 1993;159:535-48.